Current Ratio
since 2005
Calculation
Thermo Fisher Scientific Inc., current ratio, long-term trends, calculation
| Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
|---|---|---|---|---|---|
| Dec 31, 2024 | 1.66 | = | 22,137) | ÷ | 13,332) |
| Dec 31, 2023 | 1.75 | = | 24,589) | ÷ | 14,012) |
| Dec 31, 2022 | 1.48 | = | 25,229) | ÷ | 17,010) |
| Dec 31, 2021 | 1.50 | = | 20,113) | ÷ | 13,436) |
| Dec 31, 2020 | 2.13 | = | 21,957) | ÷ | 10,304) |
| Dec 31, 2019 | 1.92 | = | 11,893) | ÷ | 6,197) |
| Dec 31, 2018 | 1.73 | = | 10,625) | ÷ | 6,147) |
| Dec 31, 2017 | 1.34 | = | 9,421) | ÷ | 7,048) |
| Dec 31, 2016 | 1.44 | = | 7,021) | ÷ | 4,866) |
| Dec 31, 2015 | 1.38 | = | 5,741) | ÷ | 4,147) |
| Dec 31, 2014 | 1.22 | = | 6,540) | ÷ | 5,350) |
| Dec 31, 2013 | 3.16 | = | 9,881) | ÷ | 3,126) |
| Dec 31, 2012 | 2.31 | = | 4,835) | ÷ | 2,093) |
| Dec 31, 2011 | 1.55 | = | 4,822) | ÷ | 3,113) |
| Dec 31, 2010 | 2.42 | = | 4,135) | ÷ | 1,710) |
| Dec 31, 2009 | 2.76 | = | 4,531) | ÷ | 1,639) |
| Dec 31, 2008 | 2.82 | = | 4,346) | ÷ | 1,540) |
| Dec 31, 2007 | 1.93 | = | 3,665) | ÷ | 1,902) |
| Dec 31, 2006 | 1.70 | = | 3,660) | ÷ | 2,152) |
| Dec 31, 2005 | 1.71 | = | 1,354) | ÷ | 792) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
- Current Assets
- The current assets demonstrated an overall upward trend from 2005 to 2020, increasing significantly from US$1,354 million in 2005 to a peak of US$21,957 million in 2020. There was noticeable volatility, with a sharp increase from 2007 to 2009, a decline between 2009 and 2011, followed by steady growth from 2012 to 2020. After 2020, current assets decreased to US$22,137 million in 2024, showing some contraction in recent years but still remaining considerably higher than the early period.
- Current Liabilities
- Current liabilities also showed an overall increasing trend, rising from US$792 million in 2005 to US$13,332 million in 2024. There were significant increases around 2014 to 2017, peaking in 2022 at US$17,010 million before declining slightly in the subsequent years. This upward trend generally parallels the increase in current assets, although the liability growth appears more volatile with pronounced spikes in certain years.
- Current Ratio
- The current ratio fluctuated across the period but mostly stayed above 1, indicating that current assets generally exceeded current liabilities. The ratio peaked at 3.16 in 2013, reflecting strong short-term liquidity that year. Significant decreases occurred in 2014 and 2015, reaching a low around 1.22–1.38, with moderate improvements afterward. In the most recent years (2022 to 2024), the current ratio stabilized around 1.66 to 1.75, suggesting a balanced liquidity position but somewhat weaker than earlier peaks.
- Summary of Trends and Insights
- The data reflects substantial growth in both current assets and current liabilities over the examined period, with assets generally growing faster but accompanied by increased liabilities, indicating expansion with associated short-term obligations. The current ratio's volatility suggests periods of varying liquidity adequacy, with the company demonstrating capacity to maintain sufficient short-term assets to cover liabilities throughout the years despite occasional tightening. Recent years indicate a slight reduction in assets alongside a moderate liability decrease and stable liquidity ratios, which may point to efforts to optimize working capital or change in operational scale.
Comparison to Competitors
Thermo Fisher Scientific Inc., current ratio, long-term trends, comparison to competitors
| Thermo Fisher Scientific Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 1.66 | 0.66 | 1.26 | 1.25 | 1.40 | 1.15 | 1.60 | 1.11 | 1.36 | 1.17 | 4.73 | 2.69 |
| Dec 31, 2023 | 1.75 | 0.87 | 1.65 | 1.43 | 1.68 | 0.94 | 1.43 | 1.16 | 1.25 | 0.91 | 5.69 | 3.99 |
| Dec 31, 2022 | 1.48 | 0.96 | 1.41 | 1.25 | 1.89 | 1.05 | 1.29 | 0.99 | 1.47 | 1.22 | 5.06 | 4.83 |
| Dec 31, 2021 | 1.50 | 0.79 | 1.59 | 1.52 | 1.43 | 1.23 | 1.27 | 1.35 | 1.27 | 1.40 | 3.56 | 4.46 |
| Dec 31, 2020 | 2.13 | 0.84 | 1.81 | 1.58 | 1.86 | 1.40 | 1.40 | 1.21 | 1.02 | 1.35 | 3.63 | 4.33 |
| Dec 31, 2019 | 1.92 | 3.18 | 1.44 | 1.60 | 5.19 | 1.16 | 3.10 | 1.26 | 1.24 | 0.88 | 3.67 | 3.61 |
| Dec 31, 2018 | 1.73 | 0.98 | 2.79 | 1.61 | 1.47 | 1.73 | 3.38 | 1.47 | 1.17 | 1.57 | 4.47 | 3.43 |
| Dec 31, 2017 | 1.34 | 1.28 | 5.49 | 1.55 | 1.43 | 1.32 | 2.74 | 1.41 | 1.33 | 1.35 | 3.82 | 3.28 |
| Dec 31, 2016 | 1.44 | 1.65 | 4.11 | 1.55 | 0.97 | 1.37 | 2.22 | 2.47 | 1.78 | 1.25 | 2.56 | 2.31 |
| Dec 31, 2015 | 1.38 | 1.50 | 4.44 | 1.30 | 1.27 | 1.53 | 2.50 | 2.17 | 1.55 | 1.49 | 3.59 | 2.78 |
| Dec 31, 2014 | 1.22 | 1.41 | 4.95 | 1.73 | 1.75 | 1.09 | 3.07 | 2.36 | 1.77 | 2.67 | 3.31 | 4.20 |
| Dec 31, 2013 | 3.16 | 2.59 | 3.44 | 1.52 | 2.01 | 1.47 | 1.15 | 2.20 | 2.00 | 2.41 | 6.01 | 3.99 |
| Dec 31, 2012 | 2.31 | 2.27 | 3.81 | 1.15 | 1.80 | 1.55 | 1.44 | 1.90 | 1.90 | 2.15 | 7.37 | 3.67 |
| Dec 31, 2011 | 1.55 | — | 4.80 | 1.97 | 1.50 | 1.60 | 5.53 | 2.38 | 2.04 | 2.06 | 4.40 | 3.39 |
| Dec 31, 2010 | 2.42 | — | 3.52 | 1.97 | 1.73 | 2.09 | 2.32 | 2.05 | 1.86 | 2.11 | 3.28 | 2.23 |
| Dec 31, 2009 | 2.76 | — | 4.89 | 2.21 | 1.89 | 1.90 | 2.57 | 1.82 | 1.80 | 1.66 | 4.55 | 4.59 |
| Dec 31, 2008 | 2.82 | — | 3.12 | 2.20 | 1.53 | 0.95 | 3.52 | 1.65 | 1.35 | 1.59 | 6.23 | 4.01 |
| Dec 31, 2007 | 1.93 | — | 2.11 | 1.20 | 1.40 | 2.33 | 4.11 | 1.51 | 1.23 | 2.15 | 2.81 | 2.49 |
| Dec 31, 2006 | 1.70 | — | 1.67 | 1.59 | 1.38 | 1.91 | 3.18 | 1.20 | 1.20 | 2.20 | 10.44 | 3.07 |
| Dec 31, 2005 | 1.71 | — | 2.57 | 1.78 | 1.30 | 1.89 | 6.79 | 2.48 | 1.58 | 1.47 | 8.46 | 3.84 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Thermo Fisher Scientific Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Thermo Fisher Scientific Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 1.66 | 1.24 |
| Dec 31, 2023 | 1.75 | 1.27 |
| Dec 31, 2022 | 1.48 | 1.30 |
| Dec 31, 2021 | 1.50 | 1.36 |
| Dec 31, 2020 | 2.13 | 1.37 |
| Dec 31, 2019 | 1.92 | 1.66 |
| Dec 31, 2018 | 1.73 | 1.71 |
| Dec 31, 2017 | 1.34 | 1.74 |
| Dec 31, 2016 | 1.44 | 1.91 |
| Dec 31, 2015 | 1.38 | 1.90 |
| Dec 31, 2014 | 1.22 | 2.19 |
| Dec 31, 2013 | 3.16 | 2.17 |
| Dec 31, 2012 | 2.31 | 2.04 |
| Dec 31, 2011 | 1.55 | 2.30 |
| Dec 31, 2010 | 2.42 | 2.14 |
| Dec 31, 2009 | 2.76 | 1.95 |
| Dec 31, 2008 | 2.82 | 1.66 |
| Dec 31, 2007 | 1.93 | 1.74 |
| Dec 31, 2006 | 1.70 | 1.65 |
| Dec 31, 2005 | 1.71 | 1.82 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Thermo Fisher Scientific Inc., current ratio, long-term trends, comparison to industry (health care)
| Thermo Fisher Scientific Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 1.66 | 1.14 |
| Dec 31, 2023 | 1.75 | 1.17 |
| Dec 31, 2022 | 1.48 | 1.19 |
| Dec 31, 2021 | 1.50 | 1.24 |
| Dec 31, 2020 | 2.13 | 1.24 |
| Dec 31, 2019 | 1.92 | 1.40 |
| Dec 31, 2018 | 1.73 | 1.45 |
| Dec 31, 2017 | 1.34 | 1.49 |
| Dec 31, 2016 | 1.44 | 1.67 |
| Dec 31, 2015 | 1.38 | 1.66 |
| Dec 31, 2014 | 1.22 | 1.87 |
| Dec 31, 2013 | 3.16 | 1.93 |
| Dec 31, 2012 | 2.31 | 1.81 |
| Dec 31, 2011 | 1.55 | 1.92 |
| Dec 31, 2010 | 2.42 | 1.80 |
| Dec 31, 2009 | 2.76 | 1.75 |
| Dec 31, 2008 | 2.82 | 1.42 |
| Dec 31, 2007 | 1.93 | 1.51 |
| Dec 31, 2006 | 1.70 | 1.39 |
| Dec 31, 2005 | 1.71 | 1.64 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).